Episode Details
Back to Episodes
A New Glaucoma Gene Therapy Is Entering Human Trials — Could It Protect Vision Without Lowering Eye Pressure?
Description
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/a-new-glaucoma-gene-therapy-is-entering-human-trials-could-it-protect-vision-without-lowering-eye-pressure
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
A New Glaucoma Gene Therapy Is Entering Human Trials — Could It Protect Vision Without Lowering Eye Pressure? For more than a century, glaucoma treatment has focused on one central strategy: lower the pressure inside the eye. Pressure-lowering eye drops, laser treatment, and surgery can slow damage, but they do not directly make retinal ganglion cells more resistant to injury. Some patients continue to lose vision even when their eye pressure appears to be well controlled. ASP2767, an experimental gene therapy from Astellas, is designed around a different idea: deliver protective genes directly to retinal ganglion cells so that the cells may better survive glaucoma-related stress. The treatment is now entering its first human study, registered as NCT07770685, a combined Phase 1 and Phase 2 trial. The trial is important because it is specifically designed to test a neuroprotective treatment for progressive open-angle glaucoma, not simply another pressure-lowering drug. () The most likely interpretation of the available evidence is that ASP2767 is intended primarily to preserve surviving retinal ganglion cells and their function. It is not yet demonstrated to regenerate a damaged optic nerve, replace dead neurons, or restore established visual-field loss. The Bottom Line ASP2767 is an investigational intravitreal gene therapy. The first human trial plans to enroll approximately 156 adults with progressive open-angle glaucoma. The public trial record does not disclose the clinical vector, gene sequence, dose levels, or names of the anti-inflammatory preventive treatments. The strongest scientific trail connects ASP2767 to work from Quethera, a company acquired by Astellas in 2018. The best-matching preclinical program uses an adeno-associated virus type 2 vector to express both: Tropomyosin receptor kinase B, a receptor that supports retinal ganglion-cell survival. Mature brain-derived neurotrophic factor, a protein that activates that receptor. In mice and rats, the related construct preserved retinal ganglion cells and electrical measures of retinal ganglion-cell function after optic-nerve injury or experimentally elevated eye pressure. There is no public evidence yet that the treatment regenerates long-distance optic-nerve axons or restores permanent visual-field loss. If it works, ASP2767 would most likely be an add-on treatment used together with eye-pressure control, not a replacement for it. --- What Is ASP2767? Established facts ASP2767 is: Developed by Astellas Pharma. Intended for optic neuropathy caused by glaucoma. Administered by a single intravitreal injection into one eye. Being tested in adults with progressive open-angle glaucoma. Entering humans for the first time in the registered Phase 1/Phase 2 study. Listed in Astellas’ ophthalmology pipeline as a gene therapy for glaucoma. () The public-facing trial materials describe ASP2767 as a harmless-virus-based gene therapy. The delivered genes are expected to cause retinal nerve cells to produce proteins intended to protect them and slow further vision loss. () What has not been officially disclosed The publicly available clinical-trial listing does not identify: The exact adeno-associated virus type or engineered capsid used clinically. The promoter controlling gene expression. The